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SUMMARY
In Germany, active bat rabies surveillance was conducted between 1993 and 2012. A total of 4546
oropharyngeal swab samples from 18 bat species were screened for the presence of EBLV-1- ,
EBLV-2- and BBLV-speciﬁc RNA. Overall, 0·15% of oropharyngeal swab samples tested EBLV-1
positive, with the majority originating from Eptesicus serotinus. Interestingly, out of seven
RT–PCR-positive oropharyngeal swabs subjected to virus isolation, viable virus was isolated from a
single serotine bat (E. serotinus). Additionally, about 1226 blood samples were tested serologically,
and varying virus neutralizing antibody titres were found in at least eight different bat species. The
detection of viral RNA and seroconversion in repeatedly sampled serotine bats indicates long-term
circulation of the virus in a particular bat colony. The limitations of random-based active bat rabies
surveillance over passive bat rabies surveillance and its possible application of targeted approaches
for future research activities on bat lyssavirus dynamics and maintenance are discussed.
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INTRODUCTION
Rabies is one of the most important zoonotic dis-
eases in the world [1]. The causative agents are
negative-strand RNA viruses of the genus Lyssavirus
of the family Rhabdoviridae [2]. Today, 15 different
lyssavirus species are known to occur worldwide
and except for Mokola virus (MOKV) and Ikoma
virus (IKOV) all of them were found in bats
suggesting that species from the order Chiroptera rep-
resent the true reservoir hosts for lyssaviruses [3].
While rabies in carnivores has been known for millen-
nia and was the subject of intensive research, our
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understanding of rabies in bats concerning, e.g. epi-
demiology, prevalence, distribution and pathogen-
icity is still incomplete [4]. This is due to the fact
that in contrast to terrestrial rabies, bat rabies has
only been known for the past 100 years [3]. In
addition, bat rabies may be driven by different mech-
anisms [3]. Furthermore, the nocturnal and often
cryptic activity of bats limited studies on the occur-
rence of lyssavirus infections and their dynamics and
maintenance in relation to bat biology [5].
So far, ﬁve out of the 15 known bat-associated
lyssavirus species have been detected in Europe. The
great majority of European bat rabies cases detected
between 1977 and 2012 (n=1033, Rabies Bulletin
Europe, www.who-rabies-bulletin.org) were caused
by European bat lyssavirus type 1 (EBLV-1) and
type 2 (EBLV-2) (for review see [6]). While EBLV-1
is associated with Eptesicus spp. (Serotine bat –E. sero-
tinus, Isabelline Serotine bat –E. isabellinus), EBLV-2
has been isolated from Myotis spp. (Daubenton’s
bat –M. daubentonii, Pond bat –M. dasycneme). Con-
sequently, these bat species were considered as the
only reservoir hosts for bat-associated lyssaviruses in
Europe. However, recently novel bat lyssaviruses
have been detected in other European insectivorous
bats. Bokeloh bat lyssavirus (BBLV) was detected in
Natterer’s bats (M. nattereri) in Germany and France
in 2010 and 2012 [7, 8], whereas West Caucasian
bat lyssavirus (WCBV) and Lleida bat lyssavirus
(LLEBV) were found in Schreiber’s bent-winged
bats (Miniopterus schreibersii) in the West Caucasian
Mountains and on the Iberian Peninsula in 2003 and
2012, respectively [9, 10]. It is unknown whether
the latter two viruses use the same bat species as a
reservoir, or whether the geographically distant popu-
lations represent two distinct sibling species of
Mi. schreibersii.
In contrast to other parts of the world, all
52 European bat species are classiﬁed as endangered
and, therefore, are protected by the regulations of
Council Directive 92/43/EEC of the European Union
on the Conservation of Bats in Europe [11] or by
national legislation, which limits surveillance efforts.
Although guidelines for active and passive bat rabies
surveillance have been established by the European
research consortium, Med-Vet-Net [12], and were
later adopted by EUROBATS [13], the level of bat
rabies surveillance in Europe is still very heterogen-
eous [6]. Passive surveillance as the method of choice
focuses on investigations of bats which were found
with suspicious clinical symptoms or dead, whereas
active surveillance for bat lyssavirus infections consist-
ing of collecting and investigating micro-samples of
blood and saliva from free-living indigenous bat popu-
lations as pioneered in North America [14–16] is con-
sidered valuable for obtaining additional information.
As a consequence, active bat rabies surveillance in
free-ranging bat populations was implemented in the
UK [17, 18], France [19], Spain [20–24], Switzerland
[25], Sweden [26], Slovenia [27, 28], Serbia [29] and
Belgium [30]. While in some countries results from
passive surveillance were conﬁrmed by active surveil-
lance, the detection of virus neutralizing antibodies
(VNA) in sera of insectivorous bats indicated the pres-
ence of lyssaviruses in countries where bat rabies cases
had not yet been reported [6] resulting in speculation
as to whether bat lyssavirus infections are in fact
more frequent and more widely distributed than
assumed from passive surveillance data.
Since Germany is among the countries with the
highest frequency of bat rabies cases in Europe ([6],
Rabies Bulletin Europe, www.who-rabies-bulletin.
org) active bat rabies surveillance was initiated in
order to yield additional data on the distribution
of bat lyssaviruses known to circulate in German
bat populations, e.g. EBLV-1, EBLV-2, and BBLV
[6, 7]. The objective of this study was to test whether
active bat rabies surveillance can (i) complement pass-
ive surveillance, (ii) assist in generating new data/
information on the occurrence of bat-associated lyssa-
virus infections in indigenous bat populations, and
(iii) become a tool for wider application. Here, we
present the data and conclusions from two decades
of active bat rabies surveillance in Germany.
MATERIAL AND METHODS
Sampling
From 1993 until 2012, free-ranging bats of differ-
ent species were captured at 42 different locations
in seven German federal states, i.e. Bavaria,
Berlin, Brandenburg, Hesse, Mecklenburg-Western
Pomerania, Saxony and Saxony-Anhalt, during rou-
tine mark–capture–recapture studies in close collabor-
ation with local bat biologists (see Supplementary
Fig. S1, available online). Capture sites were selected
either randomly or based on established long-time
monitoring of indigenous bat species. None of the
colonies had a history of conﬁrmed bat rabies cases.
Bats were caught between May and September, either
during night-time using mist nets or harp traps at the
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cave entrances of swarming sites, maternity roosts
in buildings and hunting areas over bodies of
ﬂowing or standing water, or during routine inspec-
tion of artiﬁcial maternity roosts in forests. Occasion-
ally, bats were also sampled during hibernacula
(October–February).
Species of bats were identiﬁed by bat biologists
using morphological features [31, 32], and data on
sex, age, reproductive status, forearm length, and
weight were collected. Prior to release, bats were
marked with a uniquely numbered bat ring for indivi-
dual identiﬁcation (Fledermausmarkierungszentrale –
Sächsisches Landesamt für Umwelt und Geologie,
Dresden, Germany; Beringungszentrale –Zoolo-
gisches Forschungsmuseum Alexander Koenig, Bonn,
Germany).
To detect viral RNA or infectious virus in the saliva
of bats, oropharyngeal swab samples were taken using
dry sterile cotton swabs (Nerbe plus GmbH,
Germany). Swabs were placed into 500 μl sterile mini-
mum essential medium (MEM-10, with 2% strepto-
mycin). Blood of sub-adult and adult bats was taken
by puncture of the antebrachial vein [33] or the vein
in the uropatagium using a 26-gauge needle and col-
lected with a pipette into a 1 ml Eppendorf tube.
For animal welfare reasons bleeding of bats was
omitted in the case of small bats, poor general health
conditions, and signs of weakness or malnutrition.
Moreover, if no blood could be obtained after vene-
puncture further attempts were abandoned. After
sampling bats were offered 10% glucose solution as
replenishment. All samples were instantly stored at
≈4 °C in cool boxes in the ﬁeld and transferred the
same day to the laboratory. Here, oropharyngeal
swabswere spun down at 1000 rpm to retrieve absorbed
medium from the cotton swab. Serum was extracted
from blood samples after centrifugation at 1000 rpm
for 10 min. Subsequently, oropharyngeal swabs and
serum samples were stored at −80 °C until testing.
Capturing, handling, ringing, and sampling of bats
was done under supervision of bat biologists following
guidelines approved by the respective competent
authorities.
Laboratory tests
Polymerase chain reaction (PCR)
RNA from oropharyngeal swab samples (250 μl)
was extracted either using commercial guanidine-
thiocyanate-based RNA extraction followed by
column-based puriﬁcation (RNeasy Mini kit, Qiagen,
Germany), TRIzol® (Invitrogen™) or peqGOLD
TriFast™ (Peqlab Biotechnologie GmbH, Germany)
according to manufacturers’ recommendations. RNA
was re-suspended in a volume of 20 μl distilled water
and stored at −80 °C until testing. Ampliﬁcation
and detection of viral RNA was undertaken using
two different reverse transcriptase–polymerase chain
reaction (RT–PCR) methods speciﬁc for EBLV-1
and EBLV-2. While from 1993 to 2004 oropharyngeal
swab samples were tested by nested RT–PCR as
described previously [34], between 2005 and 2012
samples were investigated by a TaqMan-based quanti-
tative real-time PCR (qRT–PCR) using primers and
probes as shown in Supplementary Table S1 (available
online). For the duplex EBLV-1 and EBLV-2 assay, a
master mix consisting of 3·25 μl RNase-free water,
12·5 μl 5×QuantiTect Virus NR master mix, 0·25 μl
100×QuantiTect Virus RT mix (Qiagen, Germany),
2·0 μl speciﬁc primer-probe mix each for EBLV-1
and EBLV-2 (10 pmol EBLV-speciﬁc primers
+5 pmol EBLV-speciﬁc probes) for one reaction was
prepared and 5 μl RNA template was added. For
ampliﬁcation the following temperature proﬁle was
used: 30 min at 50 °C (reverse transcription), 15 min
at 95 °C (inactivation reverse transcriptase/activation
Taq polymerase), followed by 42 cycles of 30 s at
95 °C (denaturation), 30 s at 55 °C (annealing) and
30 s at 72 °C (elongation).
Following the discovery of BBLV in 2010 [7],
remaining samples of Myotis species (e.g. M. nattereri)
were additionally tested using a BBLV-speciﬁc
qRT–PCR as described previously [35] (Supple-
mentary Table S1). Positive control and negative
control (water) samples were analysed in parallel in
each PCR run. For the real-time PCRs Ct values
>35 were considered negative. RNA samples from
oropharyngeal swabs were pooled (n=4) and, in case
of positive results, individual RNA samples were re-
tested separately.
Rabies tissue culture infection test (RTCIT)
Virus isolation was only performed from RT–PCR-
positive oropharyngeal swab samples using RTCIT
[36]. Brieﬂy, mouse neuroblastoma cells (MNA 42/
13; Friedrich-Loefﬂer-Institut, Germany) were inocu-
lated with 200 μl of the remaining oropharyngeal
swab medium and incubated for 3 days at 37 °C and
5% CO2. A result was conﬁrmed negative after the
third consecutive cell passage.
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Sequence analysis
RTCIT-positive samples were further characterized
using sequence analysis of the N-coding region. Se-
quencing of the nucleoprotein gene was performed
with a panel of IRD-800-labelled forward and reverse
primers as described previously [37]. Sequence analy-
sis was performed using the Lasergene 6 package
(DNAstar Inc., USA).
Rapid ﬂuorescent focus inhibition test (RFFIT)
Individual serum samples (25 μl) were tested for the
presence of VNA using a modiﬁed RFFIT as de-
scribed previously [38] with an EBLV-1 isolate as
test virus [39]. In general, sera were tested in twofold
serial dilutions on mouse neuroblastoma cells (MNA
42/13) with a starting dilution of 1:10. If there was
not a sufﬁcient amount of serum available, sera were
tested with a starting dilution of 1:20. A heterologous
WHO international standard immunoglobulin (se-
cond human rabies immunoglobulin preparation,
National Institute for Standards and Control, UK)
adjusted to 1·5 IU/ml served as a positive control.
The VNA titre was expressed as the reciprocal of the
serum dilution showing a 50% reduction in ﬂuorescent
foci of the EBLV-1 test virus in vitro.
RESULTS
From 1993 until 2012, bats were caught at 42 different
locations (Supplementary Fig. S1). In four capture
sites in Brandenburg and Saxony-Anhalt sampling
was conducted repeatedly (up to six times) on an an-
nual basis, while at the remaining locations capturing
was only conducted once. During the study period, a
total of 4546 oropharyngeal swabs were taken from
18/24 bat species indigenous to Germany. The
majority of samples were collected in Saxony-Anhalt
(n=3118) and Brandenburg (n=530). The most
frequently sampled species were the noctule bat
(Nyctalus noctula) and Natterer’s bat (M. nattereri),
followed by Daubenton’s bat (M. daubentonii)
and Nathusius’ pipistrelle bat (Pipistrellus nathusii)
(Table 1). Of the 4546 oropharyngeal swabs taken,
1628 (35·8%) were screened using RT–PCR on the
presence of all three European bat lyssaviruses
known to exist in Germany (EBLV-1, EBLV-2,
BBLV), while 2312 (50·9%) samples were tested for
viral RNA of both types of EBLVs. A total of 304,
269 and 33 oropharyngeal swabs were investigated
exclusively for EBLV-1-, EBLV-2- and BBLV-speciﬁc
RNA, respectively. This resulted in a total of 4277,
4209 and 1661 individual EBLV-1-, EBLV-2-, and
BBLV-speciﬁc RT–PCR tests (Table 1).
EBLV-2- and BBLV-speciﬁc RNA was not detec-
ted in 4209 and 1661 tested swabs, respectively,
whereas by RT–PCR EBLV-1-speciﬁc amplicons
were obtained in seven of 4277 samples representing
ﬁve serotine bats (E. serotinus), one Natterer’s bat
(M. nattereri) and one Western barbastelle bat
(Barbastella barbastellus) (Table 1). Of those seven
RT–PCR-positive oropharyngeal swab samples tested
by RTCIT, viable EBLV-1 was isolated from a single
serotine bat that was captured in a maternity roost
in the village of Tornow, Brandenburg, in 1993. Se-
quence analysis of this particular EBLV-1 isolate (lab-
oratory no. 31448, GenBank accession no. KF042302)
showed a 99·9% identity in a 1356 bp fragment of the
N gene to another EBLV-1 isolate (laboratory no.
11647, GenBank accession no. KF042303) from a
rabid serotine bat obtained during passive bat rabies
surveillance in 2005 from the city of Kyritz, Branden-
burg, <10 km from the ﬁrst sampling site. Attempts to
obtain larger nucleoprotein gene-speciﬁc amplicons of
the remaining six qRT–PCR-positive samples using
conventional RT–PCR for subsequent sequencing failed.
Of the 4546 bats sampled during the study period,
a total of 1736 (36·2%) blood samples from 13 differ-
ent bat species were collected with volumes usually
ranging from 3 μl to 200 μl, equalling 1·5–100 μl of
serum. From individuals of the larger bat species,
e.g. E. serotinus, M. myotis and N. noctula, up to
500 μl of blood (250 μl serum) could be obtained. For
510 (29·4%) bats, the amount of serum was insufﬁcient
(25 μl) to be serologically analysed (Table 1). Of the
1226 sera tested against EBLV-1 using modiﬁed
RFFIT, 85·6% of samples had VNA titres of <1:10.
Virus neutralizing activity against EBLV-1 with titres
51:10 was detected in 146 (11·9%) sera from eight
bat species, while 31 (2·5%) sera from four bat species,
e.g. E. serotinus, M. myotis, B. barbastellus, N. noctula,
exhibited titres 51:20 (Table 1).
Three qRT–PCR-positive oropharyngeal swabs
and 18 sera with VNA titres 51:10 originated from
an E. serotinus maternity colony in the village of
Hartmannsdorf, Brandenburg, consisting of about
30–60 individuals (Supplementary Fig. S1, Table 2).
Of the 83 bats captured from this colony at six differ-
ent time points between 2002 and 2007, a total of
27 individuals were recaptured and resampled twice
(n=11) or three times (n=6). Overall, 17 individuals
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were either qRT–PCR positive or had VNA titres
51:10. Two qRT–PCR-positive bats (A 42019, A42
039) exhibited VNA titres <1:10 at the time of ﬁrst
sampling, of which one showed a substantial increase
in neutralizing activity 1 year later. The serotine bat
with ID A 42046 was the only individual that had
an initial VNA titre of 1:10 in 2003 which increased
fourfold when testing qRT–PCR positive 1 year
later. In ﬁve individuals a decline in VNA titres was
observed over time, whereas in three bats titres
increased (Table 2).
DISCUSSION
Although during the past 35 years >1000 bat rabies
cases were reported in Europe [6], bat rabies surveil-
lance is still very heterogeneous in terms of existing
networks of bat biologists, the number of bat species
submitted and individual bats investigated. Some
European bat species have never been investigated
for rabies, thus their role in the epidemiology of lyssa-
viruses remains elusive [6]. The discovery of the novel
lyssavirus species BBLV and LLEBV in Natterer’s
bats (M. nattereri) and Schreiber’s bent-winged
bats (Mi. schreibersii), respectively [7, 9], highlights
that besides Serotine (E. serotinus, E. isabellinus),
Daubenton’s (M. daubentonii) and Pond (M. dasyc-
neme) bats, additional bat species could serve as reser-
voirs for known or still unknown lyssavirus species in
Europe. To obtain more information on the occur-
rence of bat-associated lyssaviruses, active bat rabies
surveillance has been initiated in the Americas [14–16].
Following successful detection of rabies virus (RABV)-
speciﬁc antigen and VNAs in free-ranging American
bat populations, active bat rabies surveillance was
also initiated in Europe to obtain a better picture of
the actual incidence and prevalence of bat rabies.
The use of molecular techniques, e.g. RT–PCR, for
the detection of bat lyssavirus-speciﬁc RNA was ﬁrst
applied in Europe [24]. So far, active bat rabies sur-
veillance has been conducted in eight European
countries (for review see [6]) including Germany,
which implemented active bat rabies surveillance of
free-ranging bat colonies in addition to the already
Table 1. Screening results of 18 indigenous bat species sampled in Germany between 1993 and 2012 for the presence
of lyssavirus-speciﬁc RNA (oropharyngeal swabs) and VNAs (serum samples) using RT–PCR and modiﬁed RFFIT,
respectively
Oral swab samples tested for Serum samples tested for EBLV-1
EBLV-1 EBLV-2 BBLV Sampled Tested VNA titre
Bat species N Pos. N N N N <1:10 <1:20 51:10 51:20 51:40 51:80
B. barbastellus 105 1 83 3 58 36 10 8 11 7
E. nilssonii 40 40 4 5 0
E. serotinus 286 5 259 6 226 174 133 12 18 3 4 4
M. alcathoe 10 10 6
M. bechsteinii 94 92 48 3 1 1
M. brandtii 187 186 152 4 0
M. dasycneme 1 1
M. daubentonii 387 654 74 4 0
M. myotis 431 431 287 336 231 208 17 2 3 1
M. mystacinus 43 42 35
M. nattereri 717 1 679 696 92 23 15 8
N. leisleri 256 253 3 202 106 99 7
N. noctula 876 691 48 756 627 571 9 40 7
P. nathusii 433 395 88 18 5 2 3
P. pipistrellus 54 53 15
P. pygmaeus 193 193 164
Pl. auritus 161 144 30 17 9 8 1
Pl. austriacus 3 3 2 15 14 3 11
Total 4277 7 4209 1661 1736 1226 1050 30 115 19 7 5
VNA, Virus neutralization antibody; RT–PCR, reverse transcriptase–polymerase chain reaction; RFFIT, rapid ﬂuorescent
focus inhibition test.
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established passive bat rabies surveillance system in
1993 [40]. In previous ﬁeld studies a total of 23/52
known European bat species were tested for lyssavirus
infections [6]. During active bat rabies surveillance in
Germany, 18/24 indigenous bat species were screened
for the presence of EBLV- and BBLV-speciﬁc RNA,
some of which were underrepresented by both routine
and retrospective passive surveillance ([40], J. Schatz
et al., unpublished data). While studies in the UK
and Spain had mainly focused on reservoir species,
i.e. Daubenton’s bat (M. daubentonii), and Eptesicus
bat species [17, 20], others screened the greater
mouse-eared bat (M. myotis) [23], while only in
France, Slovenia and in one study from Spain was
a similarly high number of different bat species
sampled [19, 21, 27]. With more than 4000 orophar-
yngeal swabs and 1200 blood samples tested by
RT–PCR and RFFIT, respectively, this is one of the
most extensive active bat rabies surveillance studies
ever conducted in Europe.
While in several European studies no EBLV-
speciﬁc RNA was detected in oropharyngeal
swabs [6], we found seven oropharyngeal swab
samples positive for EBLV-1 by RT–PCR which is
in accordance with previous reports from Spain, UK
and Switzerland [13, 20, 24, 25]. The majority of
RT–PCR-positive results were associated with E. sero-
tinus bats, the natural reservoir host of EBLV-1. Of
serotine bats, 1·7% of all oropharyngeal swabs tested
positive for viral RNA. Similarly, during a 5-year
study in Spain, 2·8% of oropharyngeal swab samples
from E. isabellinus yielded viral RNA [20]. At the sero-
tine bat colony level (Hartmannsdorf, Brandenburg)
the percentage of qRT–PCR-positive swabs reached
4·7%. In contrast, up to 21% RT–PCR-positive results
were reported from a Spanish serotine bat colony tar-
geted after the detection of a bat rabies case during
passive surveillance [24]. In our study, repeated detec-
tion of viral RNA in saliva swabs from recaptured sero-
tine bats (E. serotinus) was not observed. In Spain, an
initially EBLV-1-positive E. isabellinus was negative
on recapturing [20], thus supporting observations
in experimentally infected serotine bats [41, 42].
However, unlike in other studies, not only serotine
bats but also a single Natterer’s bat and Western bar-
bastelle bats tested positive for EBLV-1-speciﬁc RNA.
Interestingly, EBLV-1 RT–PCR-positive brain tissue
was reported from a Natterer’s bat from Spain [21].
However, repeated detection of the novel BBLV in
Natterer’s bats in Germany and France [7, 8, 35] sug-
gests that this species may act as reservoir host for this
proposed new lyssavirus species and, thus, EBLV-1
Table 2. Results of RT–PCR and serological testing of 17 individual serotine bats (E. serotinus) originating from a
maternity colony in Hartmannsdorf, Brandenburg, that were either qRT–PCR positive (oropharyngeal swabs) or
had VNA titres51:10 by RFFIT when captured or recaptured between 2002 and 2005
Ring ID
2002 (July) 2003 (July) 2004 (May) 2004 (July) 2005 (July)
RT–PCR VNA RT–PCR VNA qRT–PCR VNA qRT–PCR VNA qRT–PCR VNA
A 42010 – 51:80
A 42016 – 51:80 51:40 – <1:10
A 42018 – 51:20
A 42019 – <1:20 + <1:10 – <10
A 42025 – 1:10 – 1:10
A 42028 – <1:20 – 1:10
A 42034 – 1:10 − <1:10
A 42035 – <1:10 – 51:40
A 42038 – 1:10 – <1:10 – <1:10
A 42039 + <1:10 – 51:80
A 42042 – 1:10 – <1:10 – n.a.
A 42044 – 1:10
A 42046 – 1:10 + 51:40
A 42047 – 1:10
A 42049 – 1:10
A 42051 – 1:10
A 42052 – 1:10 – 1:10 – <1:10
RT–PCR, Reverse transcriptase–polymerase chain reaction; qRT–PCR, quantitative real-time PCR; VNA, virus neutraliza-
tion antibody; RFFIT, rapid ﬂuorescent focus inhibition test.
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infections in this bat species may represent spillover
events. In Germany, E. serotinus, M. nattereri and
B. barbastellus hibernate together, e.g. in basement
vaults or different types of caves [31]. Additionally,
during passive surveillance, EBLV-1 spillover infec-
tions were also detected in other bat species in
Germany which co-hibernate with E. serotinus [40].
Generally, albeit already a high speciﬁcity of the
RT–PCR is given through hybridization probes, in
the future sequencing of RT–PCR amplicons can
conﬁrm the presence of known lyssaviruses or may
detect yet unknown variants or novel lyssaviruses.
The isolation of viable bat lyssaviruses during
active surveillance appears to be difﬁcult. During
capture studies in Spain and Finland, for example,
EBLVs were isolated from brain tissue of individual
bats that had shown clinical signs suggestive of rabies
before dying during handling [24, 43]. Markedly, in
our study infectious virus could be isolated from a
single RT–PCR-positive serotine bat. Despite the
detection of EBLV-speciﬁc RNA in very few orophar-
yngeal swab samples as reported previously [6], to our
knowledge, this is the only EBLV-1 isolation from an
oropharyngeal swab of a bat obtained during active
surveillance in Europe. Interestingly, the bat did not
show any clinical symptoms suggestive of rabies at
the time of sampling.
The low number of RT–PCR-positive animals
corroborates results obtained in experimental studies
of EBLV infection in European bats (E. serotinus,
M. daubentonii) and in North American big brown
bats (E. fuscus), in which virus shedding was rarely
detected [41, 42, 44]. However, active bat rabies sur-
veillance studies are considerably biased by random
sampling, and samples do not necessarily represent
the entire populations of each indigenous bat species.
Other reasons for the low number of RT–PCR-
positive animals could be the unknown infectious
status of the targeted bat colonies, and the fact that
not all animals of a colony can be captured at the
same time point. Furthermore, bat lyssaviruses are
causative agents considered to cause non-persistent
infections [4, 5]. While RT–PCR assays generally
have a high analytical sensitivity, a dilution effect of
viral RNA in the oropharyngeal swab sample and
possible degradation of RNA cannot be completely
excluded. Although the latter could have been avoided
using RNA stabilizing chemicals, virus isolation
attempts would then be impossible. Another limit-
ation is the diversity of lyssaviruses circulating in
European bats. At the time this study was initiated,
only EBLV-1 was known to be present in Germany.
In the meantime EBLV-2 and BBLV were detected
by passive surveillance [7, 45]. While the presence of
EBLV-2 was also analysed using a combined EBLV-1/
-2 assay, only the more recently collected samples from
this study were screened for BBLV-speciﬁc RNA.
However, this study could not provide further evi-
dence for the presence of BBLV infections in indigen-
ous bats (Table 1). Broader reacting pan-lyssavirus
PCR assays with high sensitivity as described, e.g. by
Hayman et al. [46], should improve the detection of
lyssavirus species during active surveillance.
In our study, 1226 blood samples from 10/18 bat
species sampled during the observation period were
investigated for the presence of EBLV-speciﬁc VNA.
In other European efforts, a total of 22 bat species
were the subject of serosurveillance with the number
of bat species and bats tested in individual studies ran-
ging from 1–14 and 24–976, respectively (Table 3).
Similar to previous studies from other European
countries, neutralizing activity suggesting the presence
of EBLV-speciﬁc VNAs was found in eight bat species
with a percentage of positives ranging from 7·5% [95%
conﬁdence interval (CI) 5·7–9·8] to 78·6% (95% CI
52·4–92·4) at a cut-off of 51:10 (Table 1). When the
higher cut-off was chosen VNAs were only found
in four or two bat species, respectively (Table 1).
Highest VNA titres against EBLV-1, however, were
found in its known reservoir host, i.e. E. serotinus
(Table 1). Interestingly, 28·6% (95% CI 18·4–41·5) of
56 tested individuals from a single maternity colony
in the municipality of Hartmannsdorf, a roosting
site with several EBLV-1-positive RNA in oral
swabs, had VNA titres of 51:10, resulting in a sero-
prevalence of 0–61·1% (95% CI 38·6–79·7) per year.
Our data indicate the presence of a signiﬁcant dy-
namic in virus transmission and serological response
with increasing and decreasing VNA titres in bats in
this particular colony (Table 2). This supports ﬁndings
from serological studies on Lagos bat virus which
postulated that acute transmission of bat lyssaviruses
in adapted bat hosts occurs at a far higher rate than
the occurrence of disease [47]. Our results further sup-
port previous experimental studies that although
lyssaviruses have the ability to cause clinical disease
in bats, they may not necessarily be fatal [41, 42,
44]. Unlike in other mammalian species where anti-
bodies against RABV are only detectable in the ﬁnal
stage of infection, shortly before the animal’s death,
we were able to observe seroconversion in repeatedly
captured bats (Table 2).
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Table 3. Comparison of previous serosurveillance studies conducted in Europe with the study from Germany using different modiﬁed versions of
virus neutralization assays (modiﬁed after Schatz et al. [6])
Spain UK Slovenia Belgium Switzerland France Sweden Germany
Cut-off value >1:27 (>1:5) >1:27 unknown unknown >1:25 (>1:125) >1:27 unknown not deﬁned
Bat species N pos pos in % N pos pos in % N pos pos in % N pos pos in % N pos pos in % N pos pos in % N pos pos in % N pos pos in %
Unspeciﬁed 216 0 0
B. barbastellus 2 1 9·5–90·5 36 18 50
E. isabellinus 626 51 9
E. nilssonii 47 0 0
E. serotinus 274* 0–74 299 1 0·001–1·6 17 0 0 28 7 11·4–45·2 174 29 16·7
Mi. schreibersii 168 6 3·6 17 2 2·1–37·7
M. alcathoe
M. bechsteinii 3 0 0
M. blythii 23 0 0 5 1 1·0–70·1
M. blythii/myotis 11 2 3·2–52·2
M. brandtii
M. capaccinii 3 0 0
M. daubentonii 1427 13–31 0·05–4·1 124 3 2·4 17 0 0 77 8 10·4
M. dasycneme
M. emarginatus 16 0 0 16 0
M. myotis 666 233 35 8 2 25 47 0 0 37 5 5·1–29·6 231 23 10
M. mystacinus 2 0 0
M. nattereri 1 0 0 20 0 0 8 2 25 3 0 0 23 8 34·8
N. leisleri 106 7 6·6
N. noctula 14 0 0 627 47 7·5
P. kuhlii 1 0 0 1 0 0
P. nathusii 5 3 60
P. pipistrellus 234 0 0 6 0 0 6 0 0
P. pygmaeus
Pl. auritus 5 0 0
Pl. austriacus 12 0 0 13 0 0 14 11 78·6
Plecotus spp. 8 1 13
R. euryale 16 0 0
R. ferrumeqinum 58 2 3·4 10 1 0·5–45·9
R. hipposideros 16 0 0 1 0 0
T. teniotis 34 2 5·9
References [19, 20, 22, 23] [17, 18, 49] [27] [30] [25] [19] [26] This study
* Originally described as E. serotinus [22], according to present knowledge on the phylogeography of genus Eptesicus in Europe, these results could be attributed to E. isabellinus.
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Interestingly, evidence for the presence of VNAs
against EBLV-1 was also found in M. myotis. At a
cut-off of 51:10, 9·9% (95% CI 6·7–14·5) of the
sera are considered positive, while with a cut-off
of >1:20, comparable to previous studies, the percen-
tage declines to 2·6% (95% CI 1·2–5·5). This is in con-
trast to reports in which seroprevalences between
22·3% and 45·0% were found in Spanish M. myotis
colonies [21, 23]. EBLV-1 neutralizing activity was
also detected in a single M. myotis from both
France and Belgium [19, 30]. In total, 1·1% (95% CI
0·5–2·3) of N. noctula had VNA titres51:20, whereas
a surprising 19·4% (95% CI 9·8–35·0) of B. barbastel-
lus sera exhibited high VNA activity. If a cut-off of
51:10 was chosen, the seroprevalence even increased
to 50% (95% CI 34·5–65·5) (Table 1). Besides our
study in which an oropharyngeal swab sample of a
Western barbastelle bat (B. barbastellus) also tested
EBLV-1 positive, in France a single bat from this
species was found to have VNAs [19]. With the detec-
tion of EBLV-1 RNA in oropharyngeal swabs, the
observed seroconversion probably resulted from
spillover infections from the EBLV-1 reservoir host
E. serotinus. Another possibility is the circulation of
as yet unknown EBLV-1-like virus(es). However,
since both in active and passive surveillance the num-
ber of investigated individuals of B. barbastellus is
low [6], this species needs to be further investigated.
Sporadic rabies cases in N. noctula were reported in
Europe, although further information on the virus
species is not available [6].
For various reasons it is rather difﬁcult to com-
pare results of serological testing between published
studies. Unfortunately, serological testing offers
limited insights into past exposures of clinically unsus-
picious bats as it is critically dependent on the cut-off
values used for the test [48]. Moreover, the serum
dilution is a critical point for VNA titre determi-
nation. In previous surveys, either three- or ﬁvefold
serial dilutions were applied while we used a twofold
dilution series. Furthermore, the cut-off values often
resembled the starting dilution of sera to be tested;
in general a cut-off value of 51:27 was considered
the threshold of positivity (Table 3). In our study we
did not deﬁne a cut-off value, but instead established
the VNA titres as the reciprocal of the serum dilution
showing a 50% reduction of the test virus, as done in
a study in Spain [22]. Although in general high VNA
titres tend to be speciﬁc more often, low titres rather
tend to be unspeciﬁc by resembling non-humoral
neutralization or virucidal effects. Even if high VNA
titres were speciﬁc, the extraordinary high seropreva-
lences found in Spanish M. myotis colonies [21, 23],
compared to ours, raise further questions. This could
be a true representation of regional differences in
virus circulation and dynamics; however, an inﬂuence
of the various neutralization test methods applied
cannot be excluded. Further, evidence of natural
infections in this particular species in Spain is still
lacking [6].
Another critical point is the test virus. As in a pre-
vious study [19] we used a modiﬁed RFFIT with
EBLV-1 as test virus. While this seems appropriate
for the established reservoir species E. serotinus
and E. isabellinus, it is much more difﬁcult to decide
which test virus to use in non-reservoir species. Gen-
erally, seropositivity cannot be attributed to a speciﬁc
lyssavirus, because of cross-reactivity of antibodies to
lyssaviruses within phylogroups [49]. In particular, the
recent detection of BBLV in M. nattereri exempliﬁes
that the presence of as yet unknown lyssavirus species
could account for the observed neutralizing activity in
certain bat species other than the assumed reservoir
species (Tables 1 and 3). In fact, different test viruses
were used in other serosurveillance studies. In UK,
serum samples of serotine bats and Daubenton’s
bats were separately tested against EBLV-1 (E. sero-
tinus) and EBLV-2 (Myotis spp.) [17]. VNAs in two
Natterer’s bats using EBLV-1 as test virus [50] may
indicate the presence of EBLV-1, BBLV or an as yet
undiscovered virus from phylogroup I. In Spain, sera
of different bat species were investigated using
EBLV-1 as test virus. Selected positive sera were ad-
ditionally tested against challenge virus standard
(CVS) and EBLV-2 and because of no neutralization
regarded as speciﬁc [21]. In Switzerland, serum sam-
ples of bats were tested with CVS and/or EBLV-2 as
challenge virus. Of three positive Daubenton’s bats
(reciprocal titre of 527) only one serum tested posi-
tive using CVS, while the other two seropositive
samples (EBLV-2) tested negative against CVS [25].
The latter results exemplify that even though cross-
reactivity is assumed for members of one phylogroup,
different neutralization activities may be observed,
depending on the speciﬁcity of VNAs, the titre, and
the test viruses used. For instance, when sera of
EBLV-1 and EBLV-2 experimentally infected ferrets
[34] were serologically investigated against EBLV-1
and EBLV-2, sera had lower neutralizing activity
using the heterologous test virus (T. Müller et al.,
unpublished data). Similar reactions were reported
from serological tests with Aravan virus (ARAV)
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and Khujand virus (KHUV) [51]. In this respect we
are aware of the fact that by using one test virus
only we may have missed seroconversion in other
bat species, in particular in Myotis species.
Another problem associated with serological testing
of bats is often small volume of serum obtained during
bleeding. Even from bigger species, e.g. noctule bats
(N. noctula), it was often a challenge to obtain sufﬁ-
cient blood for testing. In our opinion, from an animal
welfare point of view, serological investigations of
small bat species, e.g. Pipistrellus spp., should be
reconsidered. Micro-neutralization assays have been
used in several studies to cope with limited serum
volume [41, 52]; however, unless those tests have
been thoroughly validated for routine use, which is
often not the case, multiple testing of samples with
different challenge viruses is not practicable. Further-
more, the lack of standardized protocols including
arbitrary cut-off values, issues of pooling samples,
comparability of serological results, and cross-
neutralization represent a continuing dilemma for lys-
savirus serosurveillance in European bats [6, 53, 54].
CONCLUSIONS
Although active bat rabies surveillance has been
recommended for years [12, 13], based on our experi-
ence it provides only limited information. Given their
aetiopathology the detection of bat lyssaviruses based
on RT–PCR and virus isolation using an active ran-
dom search in free-living populations of bats is co-
incidental. Except for the serological results the low
number of RT–PCR-positive animals including the
EBLV-1 isolate obtained in our study originated
from regions in Germany where the presence of bat
rabies had already been identiﬁed through well-
established passive surveillance. Serological data
with all its current uncertainties, however, may assist
in generating new data/information on the occurrence
of bat-associated lyssavirus infections in indigenous
bat populations and hence, could be useful in comple-
menting passive surveillance. However, the detection
of cross-neutralization in bat species other than the
known reservoir species raises numerous questions
that need urgent clariﬁcation; among which is speciﬁ-
city against different known bat lyssaviruses. Based on
its current limitations and signiﬁcant logistic efforts
required, random-based active bat rabies surveillance
is not likely to become a tool to be applied more
widely and therefore cannot replace missing passive
bat rabies surveillance. Instead targeted sampling of
bat colonies with conﬁrmed bat rabies through passive
surveillance may assist in gaining deeper insights into
bat lyssavirus dynamic and maintenance.
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